OTLK Outlook Therapeutics

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
EN
07/10/2020

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotli...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: of Outlook The...

September 3, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics Requests Type A Meeting with FDA ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. ...

September 2, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug ...

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency’s issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announce...

August 28, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Reports Financial Results for Third Quarter Fisca...

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and pr...

August 14, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innova...

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the being held on July 29, 2025 in Long Beach CA. Details for the presentations are as follows:Session: Innovation Showcase Presenter: of Outlook TherapeuticsDate and Time: Tuesday, July 29, 2025, 8:35 – 9:35 AM PT For more information and to ...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch